EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Hepatitis C viremic lung transplantation to aviremic recipients: Comprehensive outcomes and post‐transplant viremia

Sarah Khan iD, Ritika Mazumder, Xiaofeng Wang, Yifan Wang, Omar T Sims, Marie Budev, William Carey

Clinical Transplantation · 2024

DOI: 10.1111/ctr.15325 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Transplantation, 2024. Verfasst von Sarah Khan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Lung Transplantation, Graft Survival, Postoperative Complications, Hepatitis C. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/aims Direct‐acting antiviral (DAA) therapy has revolutionized solid organ transplantation by providing an opportunity to utilize organs from HCV‐viremic donors. Though transplantation of HCV‐viremic donor organs into aviremic recipients is safe in the short term, midterm data on survival and post‐transplant complications is lacking. We provide a midterm assessment of complications of lung transplantation (LT) up to 2 years post‐transplant, including patient and graft survival between HCV‐viremic transplantation (D+) and HCV‐aviremic transplantation (D‐).

Methods

This is a retrospective cohort study including 500 patients from 2018 to 2022 who underwent LT at our quaternary care institution. Outcomes of patients receiving D+ grafts were compared to those receiving D‐ grafts. Recipients of HCV antibody+ but PCR‐ grafts were treated as D‐ recipients.

Results

We identified 470 D‐ and 30 D+ patients meeting inclusion criteria. Crude mortality did not differ between groups ( p = .43). Patient survival at years 1 and 2 did not differ between D+ and D‐ patients ( p = .89, p = .87, respectively), and graft survival at years 1 and 2 did not differ between the two groups ( p = .90, p = .88, respectively). No extrahepatic manifestations or fibrosing cholestatic hepatitis (FCH) occurred among D+ recipients. D+ and D‐ patients had similar rates of post‐transplant chronic lung allograft rejection (CLAD) ( p = 6.7% vs. 12.8%, p = .3), acute cellular rejection (60.0% vs. 58.0%, p = .8) and antibody‐mediated rejection (16.7% vs. 14.2%, p = .7).

Conclusion

There is no difference in midterm patient or graft survival between D+ and D‐LT. No extrahepatic manifestations of HCV occurred. No differences in any type of rejection including CLAD were observed, though follow‐up for CLAD was limited. These results provide additional support for the use of HCV‐viremic organs in selected recipients in LT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung TransplantationGraft SurvivalPostoperative ComplicationsHepatitis CHepacivirusViremiaGraft RejectionHumansFemaleMaleRetrospective StudiesMiddle AgedFollow-Up StudiesPrognosisSurvival RateRisk FactorsTissue DonorsAdultAntiviral AgentsTransplant Recipients

Stichwörter der Autor:innen

Hepatitis Cdirect‐acting antiviralsdonor pool expansiontransplantation

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
  • Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA.
  • Department of Gastroenterology, Hepatology, and Nutrition, Cleveland Clinic, Cleveland, Ohio, USA.
  • Respiratory Institute, Cleveland Clinic, Cleveland, Ohio, USA.

ORCID-Profile: Sarah Khan

Zitieren

APA

Khan, S., Mazumder, R., Wang, X., Wang, Y., Sims, O. T., Budev, M., & Carey, W. (2024). Hepatitis C viremic lung transplantation to aviremic recipients: Comprehensive outcomes and post‐transplant viremia. Clinical Transplantation. https://doi.org/10.1111/ctr.15325

Vancouver

Khan S, Mazumder R, Wang X, Wang Y, Sims OT, Budev M, et al. Hepatitis C viremic lung transplantation to aviremic recipients: Comprehensive outcomes and post‐transplant viremia. Clinical Transplantation. 2024. doi:10.1111/ctr.15325

BibTeX
@article{Khan2024,
  author = {Khan, Sarah and Mazumder, Ritika and Wang, Xiaofeng and Wang, Yifan and Sims, Omar T and Budev, Marie and Carey, William},
  title = {Hepatitis C viremic lung transplantation to aviremic recipients: Comprehensive outcomes and post‐transplant viremia},
  journal = {Clinical Transplantation},
  year = {2024},
  doi = {10.1111/ctr.15325}
}
Kostenlos starten →